Baker McKenzie advised Jefferies, Kempen & Co and Gilbert Dupont in the context of a private placement with a total amount of 25.1 million euros carried out by Nanobiotix, a nanomedicine company developing new approaches to the local treatment of cancer. The new shares, representing 9.99% of the outstanding Company shares prior to the offering, have been issued primarily with qualified institutional investors, the majority of which from the United States and Europe. The settlement took place on April 11, 2017.
This private placement will give Nanobiotix the opportunity to fund the next clinical steps of the head and neck cancer program with its product NBTXR3 in the United States and Europe. The proceeds of the offering will also be used for market preparations for NBTXR3’s launch on the European market, for the expansion of Nanobiotix’s Immuno-Oncology programme into patients and for general corporate purposes.
Jefferies and Kempen & Co acted as Joint Global Coordinators, and together with Gilbert Dupont as Joint Bookrunners, in the offering.
Nanobiotix is a leader in the field of nanomedicine, having developed new approaches to the local treatment of cancer. The Company’s first-in-class, proprietary technology, NanoXray, enhances radiotherapy energy with a view to provide a new, more efficient treatment for cancer patients, using nanoparticles to maximise the absorption of x-rays in cancerous cells. The Company started in 2016 a new preclinical research programme in Immuno-oncology with its lead product NBTXR3, which could have the potential to bring a new dimension to cancer immunotherapies. Nanobiotix went public in October 2012 and is listed on the regulated market of Euronext Paris.
Jefferies is an investment bank with offices in more than 30 major cities around the world. Kempen & Co, a Dutch merchant bank, is one of the international market leaders in life sciences & healthcare, resource efficiency & cleantech, and European real estate. Gilbert Dupont, an investment services supplier specialising in securities intermediation, is one of the leaders in the French small and medium-sized companies (“Small & Midcaps”) segment.
Baker McKenzie advised the banking pool composed of Jefferies, Kempen & Co and Gilbert Dupont with a London and Paris team. Edward Bibko, Partner and Head of Baker McKenzie’s Capital Markets Group within EMEA, and James Thompson, Partner, coordinated the transaction and directed the international placement. Raphaële François-Poncet, Partner and Head of Capital Markets and Securities Law in Paris, François-Xavier Naime, Partner, and Giuliano Lastrucci, Associate, were in charge of the French aspects of the transaction.
Nanobiotix was advised by Jones Day.
